Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01485874 · ClinicalTrials.gov registry record · Phase 1
Doxorubicin + BIBF 1120 in Patients for Ovarian Cancer
A Phase 1 study, sponsored by Hoosier Cancer Research Network.
- Terminated
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT01485874 is a Phase 1 study that was terminated before completion, run by Hoosier Cancer Research Network. The registered enrollment target is 11 participants.
The verdict
NCT01485874, a Phase 1 study, was terminated before completion, sponsored by Hoosier Cancer Research Network.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
The purpose of this trial is to determine whether BIBF 1120 can be safely combined with pegylated liposomal doxorubicin (phase I), and to determine the clinical activity of the combination in patients with platinum-resistant ovarian cancer (phase II).
Interventions
- DRUG BIBF 1120
- DRUG Doxil (Pegylated Liposomal Doxorubicin)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2011-11 |
| Est. Completion | 2015-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01485874
The ClinicalTrials.gov registry entry for NCT01485874 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoosier Cancer Research Network, which has 26 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which BIBF 1120 is the first listed.
NCT01485874 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01485874 about?
NCT01485874 is a clinical study titled "Doxorubicin + BIBF 1120 in Patients for Ovarian Cancer". The purpose of this trial is to determine whether BIBF 1120 can be safely combined with pegylated liposomal doxorubicin (phase I), and to determine the clinical activity of the combination in patients with platinum-resistant ovarian cancer (phase II).
What is the current status of trial NCT01485874?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2011-11. Estimated completion is 2015-12.
What interventions are being tested in trial NCT01485874?
The interventions under investigation include: BIBF 1120 (DRUG), Doxil (Pegylated Liposomal Doxorubicin) (DRUG).
Who is sponsoring clinical trial NCT01485874?
This trial is sponsored by Hoosier Cancer Research Network, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.